Border

Merck splits oncology into standalone business unit

Border

Merck reorganizes ahead of looming Keytruda patent cliff — Facing the anticipated loss of U.S. exclusivity for its blockbuster cancer drug Keytruda, Merck & Co. is splitting its human health business into two focused units: a standalone oncology division and a separate specialty, pharma & infectious diseases unit. The oncology arm will manage Keytruda and other cancer therapies, while non-cancer products like Winrevair and Januvia, along with vaccines, move to the other unit. The shakeup is aimed at sharpening execution and positioning the company for long-term growth beyond Keytruda’s peak sales years. Leadership changes accompany the restructure as Merck doubles down on its post-Keytruda strategy.

Click here to read the entire article.

Did you find this helpful? Share with your network!

More Tips From The Bandish Group

Border Line

The Skills Employees Need to Succeed in the Age of AI

◆

Artificial intelligence is changing the workplace, but the skills employees need in the age of AI are not necessarily new.…

#455: Interview Questions for Hiring Managers: How to Identify the Right Candidate

◆

An effective interview is about more than confirming what’s already listed on a candidate’s resume. It’s an opportunity for hiring…

Scroll to Top